E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

被引：41
|
作者：
Claudiani, Simone [1 ]
Apperley, Jane F. [1 ]
Gale, Robert Peter [1 ]
Clark, Richard [2 ]
Szydlo, Richard [1 ]
Deplano, Simona [1 ]
Palanicawandar, Renuka [1 ]
Khorashad, Jamshid [1 ]
Foroni, Letizia [1 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 08期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; YOUNG-ADULTS; IMATINIB; E13A2; TRIAL;
D O I：
10.3324/haematol.2017.168740
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E297 / E299
页数：3
相关论文
共 50 条
  • [21] Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
    Lucas, Claire M.
    Harris, Robert J.
    Giannoudis, Athina
    Davies, Andrea
    Knight, Katy
    Watmough, Sarah J.
    Wang, Lihui
    Clark, Richard E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10): : 1362 - 1367
  • [22] Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
    Su, Yi-Jiun
    Kuo, Ming-Chung
    Chen, Tsai-Yun
    Wang, Ming-Chung
    Yang, Youngsen
    Ma, Ming-Chun
    Lin, Tung-Liang
    Lin, Tung-Huei
    Chang, Hung
    Teng, Chieh-Lin Jerry
    Hsiao, Pei-Ching
    Chen, Chih-Cheng
    Wang, Po-Nan
    Shih, Lee-Yung
    CANCER SCIENCE, 2022, 113 (10) : 3518 - 3527
  • [23] A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment
    Ureshino, Hiroshi
    Takeda, Yusuke
    Kamachi, Kazuharu
    Ono, Takaaki
    Iriyama, Noriyoshi
    Ohtsuka, Eiichi
    Sakaida, Emiko
    Kimura, Shinya
    CLINICS AND PRACTICE, 2024, 14 (04) : 1216 - 1224
  • [24] Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia
    Katagiri, Seiichiro
    Gotoh, Akihiko
    Ohyashiki, Kazuma
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (02) : 332 - 334
  • [25] Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
    Marin, David
    Ibrahim, Amr R.
    Lucas, Claire
    Gerrard, Gareth
    Wang, Lihui
    Szydlo, Richard M.
    Clark, Richard E.
    Apperley, Jane F.
    Milojkovic, Dragana
    Bua, Marco
    Pavlu, Jiri
    Paliompeis, Christos
    Reid, Alistair
    Rezvani, Katayoun
    Goldman, John M.
    Foroni, Letizia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 232 - 238
  • [26] Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells
    Flis, Sylwia
    Bratek, Ewelina
    Chojnacki, Tomasz
    Piskorek, Marlena
    Skorski, Tomasz
    CANCERS, 2019, 11 (10)
  • [27] The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
    Manley, Paul W.
    Barys, Louise
    Cowan-Jacob, Sandra W.
    LEUKEMIA RESEARCH, 2020, 98
  • [28] BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR
    Zagaria, Antonella
    Anelli, Luisa
    Coccaro, Nicoletta
    Tota, Giuseppina
    Casieri, Paola
    Cellamare, Angelo
    Impera, Luciana
    Brunetti, Claudia
    Minervini, Angela
    Minervini, Crescenzio Francesco
    Delia, Mario
    Cumbo, Cosimo
    Orsini, Paola
    Specchia, Giorgina
    Albano, Francesco
    VIRCHOWS ARCHIV, 2015, 467 (03) : 357 - 363
  • [29] Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India
    Sazawal, Sudha
    Chikkara, Sunita
    Singh, Kanwaljeet
    Chaubey, Rekha
    Chandra, Dinesh
    Mishra, Pravas
    Mahapatra, Manoranjan
    Seth, Tulika
    Saxena, Renu
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2017, 27 : 24 - 27
  • [30] Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor
    Fava, Carmen
    Rege-Cambrin, Giovanna
    Dogliotti, Irene
    Gottardi, Enrico
    Berchialla, Paola
    Di Gioacchino, Bruno
    Crasto, Francesca
    Lorenzatti, Roberta
    Volpengo, Alessandro
    Daraio, Filomena
    Fantino, Cristina
    Saglio, Giuseppe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S96 - S100
12345